American biotechnology company Novavax announced on Jan. 28 that its experimental vaccine is 89.3% effective against COVID-19 and that it also showed efficacy against variants of the virus.
According to a statement released by Novavax, results from the Phase 3 trial conducted in the United Kingdom showed that the vaccine had an 89.3% efficacy rate in preventing COVID-19 and 86% against the variant that first emerged there.
“The efficacy shown against the emerging variants is also extremely encouraging. This is an incredible achievement that will ensure we can protect individuals in the U.K. and the rest of the world from this virus,” U.K. Vaccine Taskforce Clive Dix said, which partnered with Novavax for the study.
The findings of the U.K. trial, which involved over 15,000 participants aged 18 to 84, were based on 62 cases, who either received the vaccine or the placebo.
Meanwhile in South Africa, the trial involved 4,400 participants, many of whom were HIV-positive. The vaccine has demonstrated that it was effective against the variant that first emerged in the country, but the efficacy rate was lower — at 49.4%.
However, the vaccine showed 60% efficacy for trial participants who were HIV-negative, Novavax said.
According to Novavax Chief Executive Stanley Erck, his company’s vaccine is “the first vaccine to demonstrate not only high clinical efficacy against COVID-19, but also significant clinical efficacy against both the rapidly emerging U.K. and South Africa variants.”
Erck also said that the vaccine “has the potential to play an important role in solving this global public health crisis.”
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.